Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,158
Recruiting: 2,260
Ph III recruiting: 268
Growth YoY: +13.9%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 51–100 of 6,228 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07594106	REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma	recruiting	Phase 1 / Phase 2	265	Regeneron PharmaceuticalsINDUSTRY	1	Sep 28, 2026	clinicaltrials
NCT07698106	Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC	not yet recruiting	Phase 1 / Phase 2	60	University Health Network, TorontoOTHER	0	Sep 28, 2026